Investigación e Informes

Il Dong Biosciences reported that its probiotic strain IDCC 1201 improved gut symptoms and quality of life in adults with functional bowel disorders, results published in Nutrients.

A UK-Oxford study of ~70,000 US patients found Shingrix recipients had lower rates of heart disease and heart failure than those who received Zostavax.

A UK study of over 180,000 postmenopausal women found hormone therapy users had a 16% reduced risk of Alzheimer’s disease over a 13‑year follow‑up.

A study of 93 healthy women aged 20‑67 found regular aerobic exercise improves executive function after menopause.

Korean case reports show shingles lesions uncovered during in‑person visits and an elderly patient’s undisclosed medication use identified by a pharmacist.

Yuyu Pharma selected for Korea's advanced manufacturing robot demo project to automate secondary packaging of Omega soft gelatin capsules at its Jecheon plant using AI vision inspection and multi‑joint robots.

Hecto Group’s AI unit, HAI, joined the OnKoTECT consortium led by Seoul National University Bundang Hospital to develop an AI medical device for early lung cancer diagnosis and post‑surgery recurrence prediction, under a Ministry of Trade, Industry and Energy digital‑health project.

Il Dong BioScience announced that its probiotic strain IDCC 1201 reduced abdominal bloating and altered gut microbiota in a clinical trial, with results published in the journal Nutrients.

KIMCo Foundation and the AI New Drug Research Institute will support the Ministry of SMEs’ 2026 Pharma‑Bio Venture Collaboration R&D project, covering 30 AI‑driven drug discovery tasks.

ArcGen Bio has been chosen as the lead research institute for the Ministry of SMEs and Startups' pharma‑bio venture collaboration project, receiving 30 billion KRW over three years, with LG Chem joining as a co‑research partner on a multi‑specific T‑cell engager immuno‑oncology drug.

한국제약바이오협회 AI신약연구원은 9월 1일 방배동 협회 회관에서 KAIST가 개발한 차세대 바이오 AI 모델 K‑Fold 소개와 신약개발 적용 방법을 다루는 특별 세미나를 개최한다.

Phase 2 of BioNTech and Genentech's personalized mRNA colorectal cancer vaccine BNT122 was stopped early after higher deaths in the vaccine arm.